Regional media, led by Evgeny Orachevsky, Chief Executive Officer of JSC Pharmasyntez, and Dmitry Lyaskovsky, Deputy Chairman of the Irkutsk branch of SberBank, visited a Pharmasyntez plant in Irkutsk.
During the press tour, journalists were shown round a new large-scale production site of solid and sterile dosage forms of drug products launched in January this year.
Its production capacity allows producing over 4 billion tablets and 18 million vials per year which includes over 13 million vials of solutions, concentrates, and emulsions and 5 million vials of lyophilisates for solution for infusion.
It is here where lyophilisate of Remdeform (INN: Remdesivir), a drug for the new coronavirus infection treatment, is produced. Pharmasyntez received a marketing authorization for the drug product late last year. The Ministry of Healthcare of the Russian Federation included it in the treatment regimen for COVID-19. Its first commercial scale batch was released for marketing at the beginning of February. The Irkutsk Pharmasyntez plant is the only in Russia where Remdesivir is produced.
An impromptu press conference was held during the event when the heads of the companies answered journalists’ questions about cooperation, business tasks, and joint projects.
In his address to journalists, Evgeny Orachevsky noted that Pharmasyntez and SberBank had been cooperating for many years:
“The bank has been providing financial support to our company for over 15 years. In October last year, SberBank and Pharmasyntez entered into a cooperation agreement on the development of the pharmaceutical industry in the Russian Federation in compliance with the Pharma-2030 Development Strategy. The agreement provides for interaction in many areas, including joint investments, debt and equity financing, long-term financing of the JSC Pharmasyntez’ projects, digitalization and optimization of production, as well as introduction of new technologies”.
The press tour to the production site of JSC Pharmasyntez was held within the framework of a press conference given by Aleksandr Abramkin, Chairman of Baikalsky SberBank. The event was dedicated to the so-called “green finance” of the bank aimed at supporting responsible businesses. As Alexander Abramkin said:
“Today, SberBank adheres to the principles of the ESG strategy in all vectors of business which is aimed at a responsible attitude to the environment, including public health. That is why it is important for us to support enterprises that create unique products - both for the ecology of regions and for the protection of people. The cooperation with Pharmasyntez fully meets this goal. And we are glad to see that our partner's production is successfully developing. The new drug enters the process line of Pharmasyntez at the right time and it will certainly contribute to the treatment of the infection. It is pleasant to note that SberBank is also involved in this organizational process by providing the enterprise with bank resources and resources of the SberBank ecosystem”.